StockData
Sotera Health Co logo

Sotera Health Co (SHC) company profile

SHCNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$16.05−0.20 (-1.23%)

Close on Nov 17, 2026Market cap $4.58BP/E 28.2Yield –

About Sotera Health

Services-Misc Health & Allied Services, NEC, SIC 8090

The company provides outsourced terminal sterilization solutions, microbiological and analytical lab testing, and technical advisory services. It operates primarily through two segments: Sterilization Services (comprising Sterigenics and Nordion) and Lab Testing and Advisory Services (Nelson Labs). Sterigenics delivers terminal sterilization using gamma irradiation, ethylene oxide processing, and electron-beam irradiation. Nordion supplies Cobalt-60 radiation sources and manufactures gamma irradiation units for industrial sterilization and oncology applications. Nelson Labs conducts testing across healthcare product life cycles, including sterility assurance, biocompatibility, and regulatory compliance consulting. The company primarily serves medical device and pharmaceutical manufacturers, alongside food safety and advanced commercial customers.

Operations encompass a network of 62 facilities worldwide, including 48 sterilization facilities located across 13 countries as well as specialized laboratories and processing centers in North America and Europe. The enterprise supports customers in over 50 countries and employs more than 3,000 workers globally. Its headquarters is not stated in the provided text.

Summary of the business section of Sotera Health's latest annual report, written by StockData.

Company profile

Company

Legal name
Sotera Health Co
Headquarters
Broadview Heights, OH
Address
9100 South Hills Blvd, Suite 300 44147
Phone
(440) 262-1410
Employees
3,000, Dec 31, 2025
Industry
Services-Misc Health & Allied Services, NEC
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Cleveland, Ohio

Stock & identifiers

Ticker
SHC
Exchange
Nasdaq
IPO date
Nov 23, 2020
Shares outstanding
285M, Jul 30, 2026
Public float
$1.71B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1822479
CUSIP
83601L102
ISIN
US83601L1026
FIGI
BBG008LZG0Z5
Share class FIGI
BBG008LZG101
EIN
47-3531161

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael B. Petras Jr.Executive Chairman, Director4,367,305
Alton ShaderChief Executive Officer, Director579,573
Michael P. RutzPresident of Sterigenics334,279
Jonathan M. LyonsSr. Vice President, CFO217,304
Erika OstrowskiSVP, General Counsel and Sec.57,538
Alexander DimitriefFormer SVP, GC and Sec.312,040
Kenneth D. KrauseDirector14,970
David E. WheadonDirector89,882
Richard G. KyleDirector14,970
Vincent K. PetrellaDirector95,751
James NearyDirector95,751
Karen FlynnDirector54,191
Simon, ChristopherDirector34,102
Ann R. KleeDirector140,926
Sean Laurence CunninghamDirector95,751
Ruoxi ChenDirector95,751
Pincus (Bermuda) Private Equity GP Ltd. WarburgDirector118,929,897
Co-Invest Xi Lp GtcrDirector12,735,301
Investment Xi Llc GtcrDirector41,215,301
Partners Xi/A&c Lp GtcrDirector49,215,301
Fund Xi/C Lp GtcrDirector0
Warburg Pincus Partners II (Cayman), L.P.Director–
Holdco L.P. BullDirector73,822,952
Pincus Llc WarburgDirector34,102,952
Pincus & Co. WarburgDirector61,822,952

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.66M$16.71M$2.58M$64$148
FY2024$10.39M$5.07M$2.34M$54$136
FY2023$9.70M$31.19M$1.41M$67$132
FY2022$16.66M$5.91M$2.00M$33$130
FY2021$2.20M-$2.36M$658.89K$94$132
FY2020$17.20M$22.42M$5.01M$109$105

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Michael B. Petras, Jr.
Chairman and CEO
$1.13M–$8.02M$1.48M$18.07K$10.66M+3%
Jonathan Lyons
SVP, CFO
$536.54K$50.00K$2.09M$394.58K$17.99K$3.09M+44%
Michael P. Rutz
President of Sterigenics
$500.00K–$1.34M$320.25K$18.51K$2.18M-12%
Alexander Dimitrief
Former SVP and General Counsel
$600.00K–$1.55M$309.00K$2.99K$2.46M+3%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 23, 2020
Offer price
$23.00
Securities offered
46,600,000
Gross proceeds
$1.07B
Exchange
Nasdaq
First trading day
Nov 20, 2020
First-day close
$25.10+9.1%
Lock-up ends (est.)
May 19, 2021

“The initial public offering price of the common stock is $23.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed over 3,000 employees worldwide.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 23, 2020IPOInitial public offering priced (424B4 prospectus)
Nov 20, 2020ListingRegistration of securities on an exchange (Form 8-A)
Oct 9, 2020Name changeName changed from Sotera Health Topco, Inc. to Sotera Health Co

See a number that looks wrong?